Register / Log In

Anticoagulation may be safe for many outpatient procedures




Anna D. Garrett, PharmD, BCPS
Many patients who need anticoagulation also need minor outpatient surgical procedures. This raises questions regarding management of anticoagulation during the perioperative time. Although pharmacists are not responsible for making decisions about interrupting anticoagulation, it is helpful to know guidelines for common procedures.

Common outpatient procedures and recommendations regarding anticoagulation include dental procedures, gastrointestinal (GI) procedures, skin biopsies, and cataract removal.

For dental procedures, if the INR is within the therapeutic range, the risk of bleeding is minimal, including in the case of surgical extractions. Mouthwashes containing tranexemic acid may help minimize bleeding. For GI procedures, including colonoscopies and endoscopy, in which biopsies are not anticipated and overall risk is low, anticoagulation can be continued. When the procedural risk is high, but the patient has a low risk for thromboembolism, anticoagulation should be withheld as it would before any other surgery. If the risk for thromboembolism is high, bridging should be offered before surgery.

For skin biopsies, anticoagulation can be continued as these are considered minor procedures in which complications can be controlled. Finally, anticoagulation can be continued when undertaking cataract removal.

For many common outpatient procedures, anticoagulation may be safely continued.

Source: Weinberg I. Anticoagulation and surgery. Vascular medicine. http://www.angiologist.com/anticoagulation-and-surgery. Accessed February 9, 2012.


The outcry from physicians, pharmacists, and patients over disruptions in supplies of vital medications continues to draw attention on Capitol Hill and throughout the healthcare system.

Readers speak out about the title of "Dr." and pharmacies in Canada.

Requiring prior authorization may have a broader impact than expected.

Implementation of the "biosimilars" law is going well, but the exclusivity period seems to be a problem.

ASHP continues to make solving the drug shortages problem a top priority.